Sublingual atropine in the treatment of clozapine-induced sialorrhea.
Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA. Electronic address: teofilo.matossantana@yale.edu.
Teofilo E
TE
Matos Santana
Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA; VA Connecticut Healthcare System, West Haven, CT, USA.
Noah A
NA
Capurso
Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA; VA Connecticut Healthcare System, West Haven, CT, USA.
Mohini
M
Ranganathan
Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA; VA Connecticut Healthcare System, West Haven, CT, USA.
Gihyun
G
Yoon
D000286:Administration, Sublingual; D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects*; D001285:Atropine / Q000008:administration & dosage / Q000494:pharmacology*; D003024:Clozapine / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D018727:Muscarinic Antagonists / Q000008:administration & dosage / Q000494:pharmacology*; D011618:Psychotic Disorders / Q000188:drug therapy*; D012559:Schizophrenia / Q000188:drug therapy*; D012798:Sialorrhea / Q000139:chemically induced*
D014150:Antipsychotic Agents; D018727:Muscarinic Antagonists; D001285:Atropine; D003024:Clozapine